<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489554</url>
  </required_header>
  <id_info>
    <org_study_id>109661</org_study_id>
    <nct_id>NCT00489554</nct_id>
  </id_info>
  <brief_title>Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age</brief_title>
  <official_title>Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the immunogenicity in terms of antibody response and
      the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse
      events following primary vaccination of Mexican infants with pneumococcal conjugate vaccine
      GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined
      vaccine (Infanrix hexa) and rotavirus vaccine (Rotarix) in children during the first 6 months
      of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Vaccine Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Concentrations Against Protein D</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Anti-Protein D Antibodies</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
    <description>Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>Within 4 days following any vaccine dose</time_frame>
    <description>Grade 3 redness and swelling was &gt; 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>Within 4 days following any vaccine dose</time_frame>
    <description>Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature &gt; 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Unsolicited AEs</measure>
    <time_frame>Within 31 days after any vaccine dose</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Month 5</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Synflorix Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix</intervention_name>
    <description>Intramuscular injection, 3 doses.</description>
    <arm_group_label>Synflorix Vaccine Group</arm_group_label>
    <other_name>Pneumococcal conjugate vaccine GSK1024850A.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa</intervention_name>
    <description>Intramuscular injection, 3 doses.</description>
    <arm_group_label>Synflorix Vaccine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix</intervention_name>
    <description>Oral, 2 doses.</description>
    <arm_group_label>Synflorix Vaccine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between and including 6-12 weeks of age at the time of the
             first vaccination.

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Born after a gestation period of 36 to 42 weeks inclusive.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             during the period starting one month before each dose of vaccines and ending 7 days
             after dose 1 and dose 2 and one month after dose 3.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B,
             Haemophilus influenzae type b, rotavirus and/or Streptococcus pneumoniae; with the
             exception of vaccines where the first dose may be given at birth within the first two
             weeks of life according to national recommendations (e.g. Hepatitis B and BCG).

          -  History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B and
             Haemophilus influenzae type b disease.

          -  Gastroenteritis within 7 days preceding the study vaccine administration (warrants
             deferral of the vaccination).

          -  Any clinically significant history of chronic gastrointestinal disease including any
             uncorrected congenital malformation of the gastrointestinal (GI) tract,
             intussusception (IS) or other medical condition determined to be serious by the
             investigator.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of any neurological disorders or seizures.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico city</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Ruiz-Palacios G et al. Immunogenicity, safety and reactogenicity of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in Mexican infants. Abstract presented at the XIII Congreso Latinoamericano de Infectología Pediátrica (SLIPE). Guayaquil, Ecuador, 12-15 August 2009.</citation>
  </reference>
  <reference>
    <citation>Ruiz-Palacios GM, Guerrero ML, Hernández-Delgado L, Lavalle-Villalobos A, Casas-Muñoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin. 2011 Nov;7(11):1137-45. doi: 10.4161/hv.7.11.17984. Epub 2011 Nov 1.</citation>
    <PMID>22048109</PMID>
  </reference>
  <reference>
    <citation>Schuerman L et al. Population variability in antibody responses following pneumococcal conjugate vaccination: experience with the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Schuerman L et al. Population variability of opsonophagocytic activity following 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate (PHiD-CV) vaccination more limited than antibody responses. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>March 15, 2012</results_first_submitted>
  <results_first_submitted_qc>April 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2012</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary vaccination</keyword>
  <keyword>Safety</keyword>
  <keyword>Pneumococcal vaccine.</keyword>
  <keyword>Pneumococcal disease</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109661</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109661</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109661</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109661</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109661</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109661</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synflorix Vaccine Group</title>
          <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix Vaccine Group</title>
          <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations Against Pneumococcal Vaccine Serotypes</title>
        <description>Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Vaccine Serotypes</title>
          <description>Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="1.94" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="2.77" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="2.97" upper_limit="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.14" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" lower_limit="3.40" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="3.37" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" lower_limit="4.66" upper_limit="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" lower_limit="5.30" upper_limit="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" lower_limit="4.88" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.70" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations Against Protein D</title>
        <description>Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Protein D</title>
          <description>Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>ELISA units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2923.2" lower_limit="2588.6" upper_limit="3301.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes</title>
        <description>The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes</title>
          <description>The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-1 titer (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="68.2" upper_limit="130.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 titer (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670.8" lower_limit="516.1" upper_limit="871.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 titer (N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.8" lower_limit="120.6" upper_limit="183.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B titer (N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.4" lower_limit="205.5" upper_limit="580.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F titer (N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4435.4" lower_limit="3635.9" upper_limit="5410.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V titer (N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1186.1" lower_limit="955.9" upper_limit="1471.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 titer (N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168.3" lower_limit="907.4" upper_limit="1504.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C titer (N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.9" lower_limit="157.9" upper_limit="314.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F titer (N=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589.2" lower_limit="441.9" upper_limit="785.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F titer (N=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1876.3" lower_limit="1325.4" upper_limit="2656.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter</title>
        <description>The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter</title>
          <description>The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes</title>
        <description>Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes</title>
          <description>Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.24" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.22" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes</title>
        <description>The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes</title>
          <description>The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-6A titer (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.2" lower_limit="98.8" upper_limit="256.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A titer (N=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="7.3" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes</title>
        <description>Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes</title>
          <description>Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F antibody (N=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F antibody (N=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes</title>
        <description>Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes</title>
          <description>Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-1 titer (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 titer (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 titer (N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B titer (N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F titer (N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V titer (N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 titer (N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C titer (N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F titer (N=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F titer (N=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes</title>
        <description>Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes</title>
          <description>Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes</title>
        <description>Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes</title>
          <description>Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-6A titer (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A titer (N=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Anti-Protein D Antibodies</title>
        <description>Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose i.e. Month 5</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Anti-Protein D Antibodies</title>
          <description>Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 redness and swelling was &gt; 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.</description>
        <time_frame>Within 4 days following any vaccine dose</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Grade 3 redness and swelling was &gt; 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature &gt; 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.</description>
        <time_frame>Within 4 days following any vaccine dose</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
          <description>Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature &gt; 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Unsolicited AEs</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 31 days after any vaccine dose</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Unsolicited AEs</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to Month 5</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Vaccine Group</title>
            <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed up to month 5. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 4 day and 31 day post vaccination period respectively.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Synflorix Vaccine Group</title>
          <description>Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

